Akero Therapeutics to Participate in Upcoming Virtual Healthcare Conferences in March

Rhea-AI Summary

Akero Therapeutics (Nasdaq: AKRO) announced its participation in two upcoming virtual investor conferences in March 2021. The Cowen 41st Annual Healthcare Conference is scheduled for March 2, while the 2021 H.C. Wainwright Global Life Sciences Conference will take place on March 9. The company will offer live webcasts of its presentations, which will be accessible through their investor relations website. Akero is focused on developing therapies for non-alcoholic steatohepatitis (NASH), with its lead program, EFX, currently in Phase 2 clinical trials.

News Market Reaction – AKRO

+1.59%

+1.59% Session move

In the trading session that priced this news, AKRO gained 1.59%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN FRANCISCO, Feb. 23, 2021 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced that members of its management team will participate in the following virtual investor conferences in March:

• Cowen 41st Annual Healthcare Conference on Tuesday, March 2, 2021
• 2021 H.C. Wainwright Global Life Sciences Conference on Tuesday, March 9, 2021

A live webcast, if recorded, of Company presentations and Q&A will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcasts, archived replays will be available on the Company's website.

About Akero Therapeutics

Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead program, EFX, an engineered Fc-FGF21 fusion protein, is currently being evaluated in Phase 2 clinical trials as a potential treatment for NASH. Akero is headquartered in South San Francisco. Visit us at www.akerotx.com for more information.

Investor Contact:
Christina Tartaglia
212.362.1200
IR@akerotx.com

Media Contact:
Jennifer Weismann
612-716-0556
media@akerotx.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/akero-therapeutics-to-participate-in-upcoming-virtual-healthcare-conferences-in-march-301233943.html

SOURCE Akero Therapeutics

FAQ

What virtual conferences will Akero Therapeutics participate in March 2021?

Akero Therapeutics will participate in the Cowen 41st Annual Healthcare Conference on March 2, 2021, and the 2021 H.C. Wainwright Global Life Sciences Conference on March 9, 2021.

Where can I watch Akero Therapeutics' conference presentations?

Live webcasts of Akero Therapeutics' conference presentations will be available on their investor relations section at www.akerotx.com.

What is the primary focus of Akero Therapeutics?

Akero Therapeutics is focused on developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease with no approved therapies.

What is Akero's lead program for treating NASH?

Akero's lead program is EFX, an engineered Fc-FGF21 fusion protein currently undergoing Phase 2 clinical trials for NASH.